Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study

• Ensysce Biosciences (NASDAQ:ENSC) has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study.
• The trial is evaluating PF614-MPAR, an opioid candidate incorporating MPAR® technology designed to provide overdose protection.
• The study is supported by the National Institute on Drug Abuse and follows FDA Breakthrough Therapy designation for the program.

Ensysce Biosciences (NASDAQ:ENSC) announced that the first patient has been enrolled in the final stage of the PF614-MPAR-102 clinical study.

The trial is evaluating PF614-MPAR, the company’s lead opioid candidate featuring MPAR® overdose-protection technology.

This advancement marks a significant step in the clinical development of PF614-MPAR for the treatment of severe pain while aiming to reduce risks associated with traditional opioids.

The study is supported by the National Institute on Drug Abuse.

PF614-MPAR has previously received Breakthrough Therapy designation from the FDA.

Ensysce Biosciences is focused on developing next-generation opioid analgesics with built-in abuse-deterrent and overdose-protection features.

The company continues to advance its pipeline of innovative pain management therapies targeting significant unmet needs in the treatment of severe pain.